A Long-term Follow-up Study in Participants Who Received CTX001

Clinical trial NCT04208529 · ENROLLING_BY_INVITATION

Trial details

NCT number: NCT04208529
Sponsor: Vertex Pharmaceuticals Incorporated
Status: ENROLLING_BY_INVITATION
Phase: Phase 3
Study type: INTERVENTIONAL

Beta-Thalassemia Thalassemia Sickle Cell Disease Hematologic Diseases Hemoglobinopathies Genetic Diseases, Inborn Sickle Cell Anemia

Start date: 2021-01-20
Primary completion: 2039-09-30
Enrollment: 160

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.